Latest News

Double the pleasure: Stim patch delays early ejaculation: Study


 

Potential reactions

No serious adverse events were observed, Dr. Serefoglu reported. Potential adverse reactions include redness, discomfort, and localized pain, according to the company’s website.

Men should not use vPatch if they have been diagnosed with pelvic cancer, or if they have an implanted electronic device, diabetes with peripheral neuropathy, or perineal dermatologic diseases, irritations, or lesions. Other precautions include avoiding use of the vPatch in water or humid environments. The device has not been tested on use with a pregnant partner.

The disposable patches are meant for one-time use. “The miniaturized perineal stimulation device may become an on-demand, drug-free therapeutic option,” Dr. Serefoglu said.

Combining electrical stimulation with other treatment approaches may provide additional benefit, said Bradley Schwartz, DO, professor and chairman of urology at Southern Illinois University, Springfield, who moderated the session at the AUA meeting at which the results of the study were presented.

“You go from 1 to 2 minutes just with this device,” Dr. Schwartz said. “If you went from 2 to 3 minutes, you would essentially be tripling their pleasure or their time, which might make a significant difference.”

Serefoglu agreed that combining the stimulator with other treatment approaches such as topical anesthetics could increase patient satisfaction.

Comoderator Kelly Healy, MD, assistant professor of urology at Columbia University Medical Center, New York, highlighted a direction for future research: examining outcomes according to different types of relationships, as well as partner satisfaction.

“That is a perfect question that should also be considered in the future trials,” Dr. Serefoglu said. “This was mainly focused on the man’s satisfaction. But men are trying to delay their ejaculation to satisfy their partner.”

Dr. Serefoglu is on the scientific advisory board for Virility Medical, which sponsored the study. Dr. Healy had no disclosures. Dr. Schwartz disclosed ties to Cook Medical.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Babies die as congenital syphilis continues a decade-long surge across the U.S.
MDedge ObGyn
FDA approves oteseconazole for chronic yeast infections
MDedge ObGyn
Sexually transmitted infections on a 30-year rise worldwide
MDedge ObGyn
Most at-home STI testing kits fail to meet young people’s needs
MDedge ObGyn
Sex toys for science
MDedge ObGyn
FDA-cleared panties could reduce STI risk during oral sex
MDedge ObGyn
HPV strains covered by the vaccine have declined greatly in the U.S.
MDedge ObGyn
Imiquimod cream offers alternative to surgery for vulvar lesions
MDedge ObGyn
OTC meds, supplements, and other drugs may interact with HIV antiretrovirals
MDedge ObGyn
Doxycycline bests azithromycin for anorectal chlamydia in women
MDedge ObGyn